Abstract Purpose of Review We aim to summarize the current state of art about the possible
use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative …

Despite the rapid elaboration of multiple, novel systemic agents introduced for metastatic
renal cell carcinoma (mRCC) in recent years, a durable complete response remains elusive …

Background Systemic therapy (ST) can be deferred in patients who have metastatic renal
cell carcinoma (mRCC) and slow‐growing metastases. Currently, this subset of patients …

Background Recent data showed that North America has the highest incidence of renal cell
carcinoma (RCC) worldwide. Objective To assess contemporary gender-, race-, and stage …

Background The benefit of cytoreductive nephrectomy (CNT) for cancer-specific mortality
(CSM)-free survival is unclear in contemporary metastatic non-clear cell renal cell carcinoma …

Objectives Over the past decade, several systemic agents as docetaxel, cabazitaxel,
sipuleucel-T, abiraterone and enzalutamide have improved overall survival (OS) in …

Background/Aim: Nivolumab monotherapy for advanced/metastatic renal cell carcinoma
(RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses …

Hypoxia-inducible transcription factors (HIFs) drive angiogenesis and cancer cell growth,
contributing to an aggressive tumor phenotype. HIF-α protein levels and activity are …

Background The objective of this study was to investigate positive surgical margin (PSM)
rates in patients with prostate cancer treated with radical prostatectomy (RP) and assess …

Background We hypothesized that a cut-off in positive lymph node (LN) counts may
discriminate between cancer-specific mortality (CSM) rates in clinically localized prostate …